DM patients(HbA1c <
Conditions
Interventions
Participants in the pioglitazone group were administered a pioglitazone tablet (15 mg) once a day. In the event of the side effects such as oedema, the dosage of pioglitazone was reduced to half or a
Sponsors
Department of Clinical Meidicine and Development, National Cerebral and Cardiovascular Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.diabetes mellitus (HbA1c < 6.5%) 2.History of myocardial infarction
Exclusion criteria
Exclusion criteria: 1.Symptomatic CHF 2.Type I diabetes 3.History of coronary artery bypass graft 4.Severe liver and/or kidney dysfunction 5.History of allergic response to drugs 6.arteriosclerosis obliterans
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| (1) All cause mortality (2) Hospitalization due to either of the component of primary endpoints (3) Progression of diabetes (HbA1C levels > 7.0%) (4) worsening of renal function ((1) All cause mortality (2) Hospitalization due to either of the component of primary endpoints (3) Progression of diabetes (HbA1C levels less than 7.0%) (4) worsening of renal function (serum creatine levels =>2.5mg/dL or the increases of serum creatine levels by =>2mg/dL) | — |
Primary
| Measure | Time frame |
|---|---|
| Time till the first cardiovascular composite endpoint of death from cardiovascular death, and the hospitalization due to nonfatal myocardial infarction, nonfatal unstable angina, treatment with coronary revascularisation (percutaneous coronary intervention or coronary artery bypass graft) and cerebral infarction. | — |
Countries
Japan
Contacts
Public ContactMasanori Asakura
Clinical Study Support Center Japan (CSSCJ) PPAR office
Outcome results
None listed